GlassScriptPhysician profile
John C Zelazowski
NPI 1497736227
$4,514.11
in general payments reported to CMS, 2019-2025
14 companies · $936 in 2025
The $936 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $487 · 2021: $262 · 2022: $495 · 2023: $482 · 2024: $1,233 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,650.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,262.80 | 2022-2025 | Infuse, Ultra Multifocal Toric, Xiidra |
| Coopervision INC. | $609.90 | 2019-2025 | Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $403.06 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $248.37 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $161.38 | 2019-2020 | |
| Glaukos Corporation | $138.35 | 2024 | Ce-Marked Kxla System |
| Horizon Therapeutics Plc | $125.87 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $119.85 | 2021 | |
| Abbvie INC. | $114.95 | 2022 | |
| Apellis Pharmaceuticals, INC. | $103.40 | 2024 | Syfovre |
| Lkc Technologies, INC. | $71.99 | 2024 | |
| Sight Sciences, INC. | $64.65 | 2019 | |
| Oyster Point Pharma, INC. | $63.56 | 2023 | Tyrvaya |
| Ivantis, INC | $25.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zelazowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.